Tirzepatide
Mounjaro · Zepbound
A first-in-class dual agonist at both GIP and GLP-1 receptors, engineered for once-weekly dosing. FDA-approved for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea — the most potent incretin-based therapy ever commercialized, and the first to beat semaglutide head-to-head.
What is it?
Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly and marketed under two brand names: Mounjaro (type 2 diabetes, approved May 2022) and Zepbound (chronic weight management, approved November 2023; obstructive sleep apnea added December 2024). Its defining feature is dual agonism — a single molecule that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Two α-aminoisobutyric acid (Aib) substitutions protect it from DPP-4 degradation, and a C20 fatty diacid side chain at Lys20 enables albumin binding, extending the half-life to approximately five days.
The SURPASS program established tirzepatide as superior to semaglutide, insulin degludec, and insulin glargine for glycemic control in type 2 diabetes, with SURPASS-2 showing an additional ~6 kg of weight loss over semaglutide 1 mg at 40 weeks. The SURMOUNT program then extended the molecule into obesity: SURMOUNT-1 produced mean weight loss of 20.9% at the 15 mg dose over 72 weeks — roughly five percentage points above anything previously achieved with a GLP-1 monoagonist. SURMOUNT-5, the first direct head-to-head versus semaglutide for obesity, confirmed tirzepatide's superiority with 20.2% vs 13.7% weight loss at 72 weeks. As of early 2026, tirzepatide is the commercial focal point of the modern obesity drug era, with Zepbound sales trajectory tracking to overtake Ozempic on a total-dollar basis.
Mechanism of Action
Tirzepatide simultaneously activates two incretin receptors — GIP and GLP-1 — which are both expressed in the pancreas, gastrointestinal tract, and central nervous system but signal through different intracellular pathways. The dual agonism produces effects that exceed what either receptor can achieve alone:
Every step past the receptors was measured in people. What the trials cannot say is how much of the effect belongs to the GIP half.
Each step is tagged with where it was shown. A dashed red arrow marks a link the evidence does not establish.
The pathway in words
- Tirzepatide. An acylated peptide engineered to activate two receptors, GIP and GLP-1, injected once a week. Shown in: review. Source: PubMed 36050763.
- GIP and GLP-1 receptors. Both drive insulin secretion, and both are found in brain regions that regulate food intake. Shown in: review. Source: PubMed 36050763.
- Lower blood sugar. In 1,879 people with type 2 diabetes over 40 weeks, HbA1c fell 2.01 to 2.30 points against 1.86 on semaglutide 1 mg. Shown in: people. Source: PubMed 34170647.
- Weight loss. In 2,539 adults with obesity over 72 weeks, weight fell 20.9% on 15 mg against 3.1% on placebo. Shown in: people. Source: PubMed 35658024.
- More than semaglutide. In 751 adults with obesity at maximum tolerated doses for 72 weeks: 20.2% against 13.7% on semaglutide. Shown in: people. Source: PubMed 40353578.
- not isolated in people. The GIP half's share. The semaglutide comparisons differ in more than the GIP arm, so no trial here separates what it adds. Shown in: people. Source: PubMed 40353578.
Dual GIP + GLP-1 Receptor Agonism
Native GIP and GLP-1 are co-secreted by the gut after meals. Tirzepatide's dual activation restores the full incretin axis rather than just half of it. GIP receptor activation appears to enhance insulin secretion during hyperglycemia while simultaneously blunting the GI side effects that dominate GLP-1 monotherapy — a finding that helps explain why tirzepatide's efficacy exceeds semaglutide's without a proportional increase in nausea discontinuations.
Glucose-Dependent Insulin Secretion
Both GIP and GLP-1 receptors on pancreatic β-cells drive glucose-dependent insulin release. Tirzepatide's insulinotropic effect is additive across the two pathways, producing the strongest HbA1c reductions observed in any incretin therapy to date — 2.1–2.5 percentage points in SURPASS-2 vs 1.9 for semaglutide 1 mg. Hypoglycemia risk remains low because both receptors are glucose-gated.
Central Appetite Suppression
Tirzepatide acts on hypothalamic and brainstem nuclei that regulate food intake. GLP-1 receptor engagement in the arcuate nucleus reduces hunger through POMC/CART activation; GIP receptor engagement in overlapping but non-identical regions appears to provide additional appetite suppression. The result is a more profound quieting of 'food noise' than GLP-1 monotherapy alone produces — the dominant driver of tirzepatide's obesity efficacy.
Gastric Emptying & Satiety
Like GLP-1 agonists, tirzepatide slows gastric emptying, prolonging post-prandial satiety. The effect is comparable in magnitude to semaglutide but — in clinical data — appears to attenuate faster, which may explain the somewhat lower rates of persistent nausea and vomiting at maintenance dose.
Lipid Handling & Adipose Effects
Emerging evidence suggests GIP receptor activation has direct effects on adipose tissue — promoting lipid buffering and potentially protecting against ectopic fat deposition. Tirzepatide produces more favorable lipid panel changes than GLP-1 monotherapy, with notable reductions in triglycerides and apolipoprotein B that exceed what weight loss alone predicts.
Published Research
Tirzepatide has the deepest and fastest-accumulating clinical dataset of any peptide drug in the modern obesity and diabetes era. The SURPASS program (T2DM) and SURMOUNT program (obesity) together span 10+ Phase III trials with over 20,000 randomized participants. The list below highlights the landmark studies establishing efficacy, head-to-head superiority, and indication expansion.
SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head in Obesity
First direct comparison. Tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide at 72 weeks in 751 adults with obesity and no diabetes — a 47% greater relative weight loss. Waist circumference reduction -18.4 cm vs -13.0 cm. Tirzepatide also had fewer GI-related discontinuations (2.7% vs 5.6%).
SURMOUNT-OSA: Tirzepatide for Obstructive Sleep Apnea
In 469 adults with moderate-to-severe OSA and obesity, tirzepatide reduced apnea-hypopnea index by 25–29 events/hour vs placebo over 52 weeks. Supported FDA approval of Zepbound for OSA in December 2024 — the first pharmacologic treatment for OSA ever approved.
SURMOUNT-1 3-Year Extension: Obesity & Diabetes Prevention
In participants with obesity and prediabetes, 3 years of tirzepatide produced sustained weight loss and a 94% relative risk reduction in progression to type 2 diabetes vs placebo. Demonstrates durability and a disease-modifying signal.
SURMOUNT-2: Tirzepatide in Obesity with Type 2 Diabetes
In 938 adults with both obesity and T2DM, tirzepatide produced 12.8% (10 mg) and 14.7% (15 mg) weight loss at 72 weeks vs 3.2% on placebo — substantially exceeding prior GLP-1 data in this population where weight loss is historically blunted.
SURMOUNT-1: Tirzepatide Once Weekly for Obesity
Landmark obesity trial. 2,539 adults without diabetes, BMI ≥30 (or ≥27 with comorbidity). Mean weight loss of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) at 72 weeks vs 3.1% placebo. Basis for Zepbound FDA approval.
Tirzepatide as a Dual GIP/GLP-1 Co-Agonist: Mechanistic Basis for Enhanced Effectiveness
Canonical mechanistic review by Nauck & D'Alessio. Synthesizes how dual receptor engagement outperforms GLP-1 monoagonism across five Phase III trials, with unmatched reductions in HbA1c (1.24–2.58%) and body weight (5.4–11.7 kg) driven by complementary actions on β-cells, appetite regulation, and lipid handling.
SURPASS-4: Tirzepatide vs Insulin Glargine in High-CV-Risk T2DM
In 2,002 adults with T2DM and elevated cardiovascular risk, tirzepatide produced superior A1C control and weight loss vs insulin glargine over 52 weeks, with no increase in major adverse cardiovascular events. Strongest evidence to date of cardiovascular safety for this drug class.
SURPASS-2: Tirzepatide vs Semaglutide in Type 2 Diabetes
In 1,879 adults with T2DM inadequately controlled on metformin, all three tirzepatide doses produced superior A1C and weight reductions vs semaglutide 1 mg at 40 weeks. Weight loss of -7.6, -9.3, and -11.2 kg across tirzepatide doses vs -5.7 kg for semaglutide. Established tirzepatide as the superior incretin monotherapy for diabetes.
Dosing Data
Tirzepatide is prescription-only. The rows below are the current US labels for Mounjaro and Zepbound, as DailyMed published them on September 30, 2026. The 2.5 mg starting dose is for getting used to the drug; Zepbound's label says it is not a maintenance dose.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
→ Full Tirzepatide dosage guide — the Mounjaro and Zepbound escalation from 2.5 mg to 15 mg.
Side Effects & Contraindications
Reported Side Effects
Based on Phase III SURPASS and SURMOUNT trial data plus post-marketing surveillance. The side-effect profile is qualitatively similar to GLP-1 monotherapy but quantitatively somewhat milder at equivalent efficacy, likely due to the GIP component:
Contraindications & Cautions
Based on FDA prescribing information for Mounjaro and Zepbound. Absolute and relative contraindications:
Legal Status
Tirzepatide is a prescription medication approved in every major market. Unlike semaglutide, tirzepatide has not been subject to an extended FDA shortage declaration — compounded tirzepatide was added to the FDA's Do Not Compound list in March 2025 after Eli Lilly's supply caught up with demand, so large-scale compounding is no longer permitted in the US.
Frequently Asked Questions
?What is tirzepatide used for?
Tirzepatide is FDA-approved for three indications: type 2 diabetes (as Mounjaro, approved 2022), chronic weight management in adults with obesity or overweight with a weight-related comorbidity (as Zepbound, approved 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity (as Zepbound, added December 2024). It is the first medication ever approved for pharmacologic treatment of OSA.
?How much weight can you lose on tirzepatide?
In the SURMOUNT-1 trial, adults without diabetes on the 15 mg dose lost an average of 20.9% of body weight at 72 weeks, compared with 3.1% on placebo. About one-third achieved ≥25% weight loss. At the 10 mg dose the mean was 19.5%, and at 5 mg it was 15.0%. Weight loss plateaus around 60–72 weeks and is maintained with continued treatment; discontinuation typically leads to substantial regain.
?What is the difference between Mounjaro and Zepbound?
Same active molecule (tirzepatide), same vial, same dosing range — different FDA indications and insurance coverage. Mounjaro is approved only for type 2 diabetes; Zepbound is approved for chronic weight management and OSA. Your prescriber's choice of brand depends on your indication, because insurance typically only covers the brand matching your diagnosis. Clinically, the drugs are interchangeable.
?Tirzepatide vs semaglutide — which is better?
For weight loss, tirzepatide is superior. The SURMOUNT-5 head-to-head trial (NEJM 2025) showed tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide at 72 weeks — a 47% greater relative reduction. Tirzepatide had fewer GI-related discontinuations (2.7% vs 5.6%). Semaglutide still has the larger cardiovascular outcomes dataset (SELECT trial), so a patient's comorbidity profile can tip the choice. See our comparison article for a detailed breakdown.
?What are the side effects of tirzepatide?
The most common are gastrointestinal: nausea (18–33% during titration), diarrhea (~20%), constipation (~11–14%), and vomiting (~8–13%). These are largely dose-dependent and improve with slower titration. Rare but serious risks include pancreatitis, gallbladder disease, worsening of diabetic retinopathy with rapid glycemic improvement, and a boxed warning for medullary thyroid carcinoma based on rodent data. At comparable efficacy, tirzepatide's GI discontinuation rate is roughly half that of semaglutide.
?How long do you have to take tirzepatide?
Indefinitely, if the indication persists. Tirzepatide is a chronic therapy for chronic conditions — both diabetes and obesity are relapsing-remitting. Discontinuation studies show that weight regain begins within weeks and continues for at least a year. A SURMOUNT-4 withdrawal substudy demonstrated that stopping tirzepatide after 36 weeks led to regaining about 14% of body weight over the subsequent 52 weeks, while continued treatment produced additional weight loss.
?Can I get tirzepatide from a compounding pharmacy?
As of April 2026, large-scale compounding of tirzepatide is not FDA-permitted. Tirzepatide was removed from the FDA drug shortage list in late 2024, and the enforcement deadline for compounders expired March 2025. LillyDirect now offers self-pay vials directly from Eli Lilly at a lower cost than pen injectors, which has reduced — but not eliminated — demand for compounded versions. 503A patient-specific compounding remains possible under narrow clinical circumstances.
?Does tirzepatide cause muscle loss?
All weight loss — pharmacologic or behavioral — includes some lean-mass component. SURMOUNT-1 body composition data showed approximately 34% fat mass reduction and 11% lean mass reduction at the highest dose — a roughly 3:1 ratio favoring fat loss, which is more favorable than typical dietary weight loss. Resistance training and adequate protein intake (≥1.2 g/kg/day) further reduce lean-mass loss.
?Why does tirzepatide work better than semaglutide?
Tirzepatide activates two incretin receptors (GIP and GLP-1) while semaglutide activates only GLP-1. The GIP contribution appears to add appetite suppression through distinct central pathways, enhance β-cell function during hyperglycemia, and affect adipose tissue directly. Mechanistically, the dual action produces additive effects on glucose control and weight — and may also blunt the GI side effects that limit GLP-1 monotherapy dosing.
?Can you drink alcohol on tirzepatide?
No absolute contraindication, but cautions apply. Tirzepatide slows gastric emptying, which can prolong and intensify alcohol's effects. Emerging observational data suggest incretin therapies reduce alcohol craving — some patients report spontaneously reducing intake. Heavy drinking increases pancreatitis risk, which is already a class-level concern. Most prescribers advise moderate drinking only, especially during titration.
References
- [fda-pi] Mounjaro (tirzepatide) Prescribing Information. Eli Lilly.
- [fda-pi] Zepbound (tirzepatide) Prescribing Information. Eli Lilly.
- [clinical-trial] Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." N Engl J Med, 2022;387:205-216. PMID: 35658024.
- [pubmed] Aronne LJ, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." N Engl J Med, 2025;393(1):26-36. PMID: 40353578.
- [pubmed] Malhotra A, et al. "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity." N Engl J Med, 2024;391(13):1193-1205. PMID: 38912654.
- [pubmed] Jastreboff AM, et al. "Tirzepatide for Obesity Treatment and Diabetes Prevention." N Engl J Med, 2025;392(10):958-971. PMID: 39536238.
- [pubmed] Garvey WT, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial." Lancet, 2023;402(10402):613-626. PMID: 37385275.
- [pubmed] Nauck MA, et al. "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction." Cardiovasc Diabetol, 2022;21(1):169. PMID: 36050763.
- [pubmed] Del Prato S, et al. "Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial." Lancet, 2021;398(10313):1811-1824. PMID: 34672967.
- [pubmed] Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med, 2021;385(6):503-515. PMID: 34170647.
Sources & Citations
Molecular data from FDA prescribing information and PubChem. Clinical trial data from the SURPASS and SURMOUNT programs as published in peer-reviewed journals (NEJM, Lancet, JAMA). Legal status information current as of April 2026. Dosing protocols reflect current FDA-approved labeling for Mounjaro and Zepbound. This page is reviewed and updated monthly. It is educational content and does not constitute medical advice.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.